IGF2 and breast cancer: Further supporting the ability of RAGE inhibition to hamper the IR and IGF-1R-mediated effects, we demonstrated that FPS-ZM1 serves as a negative modulator of oncogenic signals prompted in response to both IGF-1 and IGF-2 in BC cells.